BiotechTube

ATYR1940 + Placebo

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Limb-Girdle Muscular Dystrophies

Conditions

Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy

Trial Timeline

Nov 30, 2015 → Oct 5, 2016

NCT ID
NCT02579239

About ATYR1940 + Placebo

ATYR1940 + Placebo is a phase 1/2 stage product being developed by aTyr Pharma for Limb-Girdle Muscular Dystrophies. The current trial status is completed. This product is registered under clinical trial identifier NCT02579239. Target conditions include Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02579239Phase 1/2Completed

Competing Products

3 competing products in Limb-Girdle Muscular Dystrophies

See all competitors
ProductCompanyStageHype Score
DeflazacortPTC TherapeuticsPhase 3
74
SRP-9005 + CorticosteroidSarepta TherapeuticsPhase 3
72
SRP-9003 + GlucocorticoidSarepta TherapeuticsPhase 3
72

Other Products from aTyr Pharma

Efzofitimod 1 mg/kg + Efzofitimod 3 mg/kg + PlaceboPhase 2
44
efzofitimod 450 mg + efzofitimod 270 mg + PlaceboPhase 2
44
ATYR1940Phase 1/2
33
ATYR1940Phase 1/2
33
Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or Placebo + Efzofitimod 5.0 mg/kg or PlaceboPhase 1/2
33